Voyager Therapeutics (VYGR) Current Leases (2019 - 2026)
Voyager Therapeutics (VYGR) posted Current Leases of $7.4 million for Q1 2026, down 6.08% sequentially from $7.8 million in Q4 2025, and down 0.9% YoY from $7.4 million in Q1 2025.
Voyager Therapeutics (VYGR) Current Leases (2019 - 2026) Analysis & Trends
Voyager Therapeutics has reported Current Leases for 8 years, with the latest figure at $7.4 million in Q1 2026.
- Quarterly Current Leases fell 0.9% year-over-year to $7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.4 million (down 0.9% YoY) and the FY2025 annual result came in at $7.8 million, up 8.48% from the prior year.
- Current Leases eased to $7.4 million in Q1 2026 per VYGR's latest filing, from $7.8 million in the prior quarter.
- Over five years, Current Leases peaked at $7.8 million in Q3 2025 and troughed at $2.5 million in Q2 2022.
- A 5-year average of $5.4 million and a median of $5.9 million in 2024 frame the typical range for Current Leases.
- The sharpest annual moves came in 2022 and 2024: Current Leases plunged 49.17% in 2022, then surged 125.84% in 2024.
- Over 5 years, Current Leases stood at $2.8 million in 2022, then increased by 12.99% to $3.2 million in 2023, then soared by 125.84% to $7.2 million in 2024, then increased by 8.48% to $7.8 million in 2025, then fell by 6.08% to $7.4 million in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $7.4 million, $7.8 million, and $7.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 45.93 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Voyager Therapeutics | 201.32 Mn | 84.98 Mn | - | 6.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.88 Mn |
| Mar 31, 2026 | 7.36 Mn |
| Dec 31, 2025 | 7.84 Mn |
| Sep 30, 2025 | 7.85 Mn |
| Jun 30, 2025 | 7.64 Mn |
| Mar 31, 2025 | 7.43 Mn |
| Dec 31, 2024 | 7.23 Mn |
| Sep 30, 2024 | 6.98 Mn |
| Jun 30, 2024 | 6.74 Mn |
| Mar 31, 2024 | 5.94 Mn |
| Dec 31, 2023 | 3.20 Mn |
| Sep 30, 2023 | 3.11 Mn |
| Jun 30, 2023 | 3.01 Mn |
| Mar 31, 2023 | 2.92 Mn |
| Dec 31, 2022 | 2.83 Mn |
| Sep 30, 2022 | 2.75 Mn |
| Jun 30, 2022 | 2.53 Mn |
| Mar 31, 2022 | 5.75 Mn |
| Dec 31, 2021 | 5.57 Mn |
| Sep 30, 2021 | 5.25 Mn |